The mechanism of PARP inhibitor action is identified
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
List view / Grid view
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
Researchers have discovered two distinct lineages of Fusobacterium nucleatum, which has great implications for colorectal cancer screening and therapeutics.
Using in situ sequencing, a collaborative research group analysed 260 genes and discovered new sub-structures in MS lesions.
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
The findings from DNA and RNA sequencing in primary and metastatic UTUC tumours could lead to strategies to improve patient outcomes.
Use of the whole liver could revolutionise the development of viral vectors, providing more effective treatments for inherited diseases.
The Organoid Group have discovered a link between FBXW7 mutations and the EGFR signalling pathway, which could improve colorectal cancer treatments.
Scientists have examined gene activity in mice models, noting important indicators of liver disease severity which may be used as therapeutic strategies.
Inhibiting the LDHA and GOT1 enzymes could prevent cancer cells’ ability to produce energy, without affecting healthy cells.
An intravenous treatment to block lnc-HLX-2-7 from binding to the HLX promoter shrunk medulloblastoma tumours, prolonging survival in mice.
A condensed version of the SMN2 gene could improve discovery of potential therapies for spinal muscular atrophy and other conditions.
Exhibiting an excellent angiogenic effect, the stem cell therapy could provide an alternative to angioplasty procedures.
New findings show that age-related MC4R+ cilia shortening causes middle-aged obesity and leptin resistance, which could lead to obesity treatment.
A lab generated monoclonal antibody prevented EBV infection and EBV lymphomas in rodent models and could have future clinical applications.
The new findings could lead to a therapeutic target for immune-related disorders, like multiple sclerosis.